- A defense of the 50-yer mortgage.
- Health insurance companies have done well under Obamacare.
- Why it will be difficult for someone to work for the Mamdani administration.
- Mamdani: “We will prove that there is no problem too large for government to solve, and no concern too small for it to care about.”
- Obamacare: From 2013 to 2026. the premium for a benchmark silver plan has nearly tripled – growing from $232 $625. The average deductible has nearly doubled – growing $2,425 to $5,304.
- US men and women are marrying late and having fewer children.
Category: Health Economics & Costs
Obamacare is Obsolete and Incompatible with Personalized Medicine
Under Obamacare patient power has only gotten worse. In 2023 I paid nearly $8,000 for a health plan that required I spend a similar amount on medical care before it paid a nickel of my medical bills. The only health care dollars I controlled were the ones I took from my own pocket. Of course, that is how it is supposed to work in other markets. The difference is that government regulates risk. If I want a method to limit my risk of a costly, catastrophic health condition, I must buy Obamacare.
Thursday Links
- Cato: How Joe Biden engineered a 21 percent expansion of food stamp benefits.
- Economic study: Sales of Tesla’s electric vehicles would have been 67 percent to 83 percent higher but for Elon Musk’s politicking.
- Could Guam become our 51st state?
- The United States had 196,000 foreign-born doctors in 2000/01, which was 24.4% of all doctors in the country. By 2020/21, this rose to 291,000, or 29.7% of all doctors in the country. For nurses, the United States had 336,000 foreign-born nurses in 2000/01, or 11.9% of the total, and 736,000 by 2020/21, or 17% of the total nurses in the US.
- Interview with Sachin Jain.
- Hospitals are incompetent monopolists.
Should the FDA Make Drugmakers Prove their Drugs Work: Part II
How tough should the U.S. Food and Drug Administration (FDA) be when approving drugs? Currently drugmakers must not only show their drugs are safe (Phase 0 and Phase 1 trials), but also, they have the desired effect on the body for most people (Phase 2 and Phase 3).